Murine IFN-γ ELISpot Set
Product Specifications
- Catalogue N°
- 862.031.001 - 1 x 96 Discovery (plate not included)
862.031.001P - 1 x 96 Discovery (non-sterile plate)
862.031.001S - 1 x 96 Discovery (sterile plate)
862.031.005 - 5 x 96 (plates not included)
862.031.005P - 5 x 96 (non-sterile plates)
862.031.005S - 5 x 96 (sterile plates)
862.031.010 - 10 x 96 (plates not included)
862.031.010P - 10 x 96 (non-sterile plates)
862.031.010S - 10 x 96 (sterile plates)
862.031.015 - 15 x 96 (plates not included)
862.031.015P - 15 x 96 (non-sterile plates)
862.031.015S - 15 x 96 (sterile plates)
862.031.020 - 20 x 96 (plates not included)
862.031.020P - 20 x 96 (non-sterile plates)
862.031.020S - 20 x 96 (sterile plates) - Target species
- Murine
- Specificity
- Recognizes natural murine IFN-g
- Incubation
- 3h after cell stimulation
- Cross Reaction
- No cross reactivity with other murine cytokines
- Kit Content
- Diaclone ELISpot Sets include capture and detection antibodies, Streptavidin - Alkaline Phosphatase conjugated, BSA, BCIP/NTB and blocking reagent.
- Additional Information
- Spots read visually or with reader
- Synonym
- IFN-g
- IFN-gamma
References
- Abadie, V. et al.,PLoS One,2009; 4(12): e8159 - Pubmed link
- Adotevi, O.et al., Blood,2010; 115(15): 3025-3032 - Pubmed link
- Adriouch, S. et al., Front Microbiol.,2011; 2: 199 - Pubmed link
- Ascough, S. et al., Front Microbiol.,2016;6:1506 - Pubmed link
- Ascough, S. et al., PLoS Pathog.,2014; 10(5): e1004085 - Pubmed link
- Attaf, M. et al., Sci Rep.,2016; 6: 35006. - Pubmed link
- Bergwerf, I. et al.,BMC Biotechnol.,2009; 9: 1. - Pubmed link
- Bialkowski, L. et al., Sci Rep.,2016;6:22509 - Pubmed link
- Bonduelle, O. et al., J. Immunol., 2012; 188: 952 - 956 - Pubmed link
- Calvet, C. Y. et al., Mol Ther Methods Clin Dev.,2014;1:14045 - Pubmed link
- Chen A. et al., J. Virol., 2005; 79(9): 5568 - 5576 - Pubmed link
- Cox, F. et al., PLoS One,2015; 10(12): e0145243 - Pubmed link
- Dosset,M. et al.,Oncoimmunology. 2018 Mar 15;7(6):e1433981. - Pubmed link
- Dunachie, S.J. et al.,Sci Rep. 2017 Sep 22;7(1):12143. - Pubmed link
- Gaidot, A. et al., Blood,2011;117(10):2975-2983 - Pubmed link
- Gallou, C. et al., Oncotarget,2016; 7(37): 59417-59428 - Pubmed link
- Guan, X. J. et al.,World J Gastroenterol.,2002; 8(2): 294-7 - Pubmed link
- Hardet, R. et al., Mol Ther.,2015;24(1): 87-95 - Pubmed link
- Herrmann, A. et al., J Clin Invest.,2014; 125(6): 2547 - Pubmed link
- Herrmann, A. et al.,Cancer Res., 2010; 70 (19) :7455-7464. - Pubmed link
- Huang, J. et al.,BMC Immunol.,2012; 13: 50 - Pubmed link
- Johansen, P. et al., Clin. Vaccine Immunol.,2011; 18(6): 907-913 - Pubmed link
- Kujawski, M. et al., Cancer Res.,2010; 70(23): 9599-9610 - Pubmed link
- Le Gouellec, A. et al.,Mol Ther.,2013; 21(5): 1076-86 - Pubmed link
- Li H. et al., J. Immunol., 2005; 174(1): 195 - 204 - Pubmed link
- Li, H. T. et al., World J Gastroenterol.,2005; 11(19): 2858-63. - Pubmed link
- Lin, T. et al., Clin Exp Immunol.,2006; 144(2): 319-25. - Pubmed link
- Luo, D. et al., Infect Immun.,2006; 74(5): 2734-41. - Pubmed link
- Mahnke, Y. D.et al.,Immunology,2005; 115(3): 325-36. - Pubmed link
- Martin Caballero, J. et al.,PLoS One,2012; 7(12): e52976 - Pubmed link
- McIlroy, D. et al.,Mol Ther.,2009;17(8): 1473-81 - Pubmed link
- Musson, J. A. et al., Infect. Immun.,2010; (78): 4356-4362 - Pubmed link
- Musson, J. A. et al.,J. Immunol.,2014;193(12):6041-6049 - Pubmed link
- Pere, H. et al., Blood,2011;118(18):4853-4862 - Pubmed link
- Qiu, J. et al., Clin. Vaccine Immunol.,2011: CVI.00254-10 - Pubmed link
- Qiu, J. et al.,World J Gastroenterol.,2006; 12(3): 473-8. - Pubmed link
- Quigley, K. J. et al., Am J Respir Crit Care Med.,2015; 191(11): 1250-64 - Pubmed link
- Ramakrishna L. et al., J. Virol., 2004; 78(17): 9174 - 9189 - Pubmed link
- Reynolds, C. et al., J. Immunol.2015;194(10):4814-4824 - Pubmed link
- Reynolds, C.J. et al.,Sci Rep., 2018 Jan 12;8(1):672 - Pubmed link
- Rojas, J. M. et al.,Vet Res.,2015;45:30 - Pubmed link
- Rojas, J.M. et al.,Vet Res., 2017 Nov 21;48(1):79. - Pubmed link
- Ru, Z. et al.,PLoS One,2012;7(3): e32247 - Pubmed link
- Sandoval, F. et al., Science Translational Medicine,2013;5:172ra20 - Pubmed link
- Seyed, N. et al.,PLoS One, 2014; 9(10): e108848 - Pubmed link
- Shi, T. D. et al., World J Gastroenterol.,2004; 10(8): 1222-6. - Pubmed link
- Singh, M. et al.,PLoS One,2012; 7(6): e38491. - Pubmed link
- Someya K. et al., J. Virol., 2004; 78(18): 9842 - 9853 - Pubmed link
- Thalmensi, J. et al.,Oncoimmunology,2016; 5(3): e1083670. - Pubmed link
- Tian, G. et al.,World J Gastroenterol.,2004;10(2): 200-4 - Pubmed link
- Tran, L. et al., J Biomed Biotechnol.,2012: 878657. - Pubmed link
- Tran, T. et al., Clin. Cancer Res.,2016; 22(16): 4133-4144 - Pubmed link
- Tsunoda, I. et al., J Virol.,2005; 79(23): 14640-6. - Pubmed link
- Waeckerle-Men, Y. et al., Nephrol Dial Transplant., 2007; 22: 1527 - 1536 - Pubmed link
- Yan, L. et al., Infect. Immun.,2008; IAI.00245-08. - Pubmed link
- Zhang, Y. et al., Oncol Rep.,2015; 33(6): 2695-702 - Pubmed link
- Gao, X. et al.,Mol Med Rep. 2018 Jul;18(1):315-321. - Pubmed link
- Rabu, C. et al., Oncoimmunology. 2019; 8(4): e1560919 - Pubmed link
- Trus, I. et al., Front Immunol. 2019; 10: 3077. - Pubmed link
- Ishii, K. et al., Virology. 2006 Aug 1; 351(2): 368–380. - Pubmed link
- Rossi, M. et al., Front Immunol. 2021; 12: 695056. - Pubmed link
- Tomás-Cortázar, J. et al., Front Immunol. 2021; 12: 767359. - Pubmed link
- Reynolds C.J. et al., Science. 2022 Jul 15;377(6603) - Pubmed link
- Wetzel, A. et al., Front Immunol. 2021; 12: 812171. - Pubmed link
Related products
- 855.000.000 - Anti-Human IFN-γ Azide Free
- 855.001.019 - Anti-Human IFN-γ FITC Conjugated
- 855.002.019 - Anti-Human IFN-γ PE Conjugated
- 879.000.001 - Anti-Human IFN-γ Capture Antibody
- 879.000.002 - Anti-Human IFN-γ Detection Antibody
- 850.900.048 - Human IFN-γ High Sensitivity ELISA Kit
- 860.050.048 - Murine IFN-γ ELISA Kit
- 865.010.048 - Rat IFN-γ ELISA Kit
- 950.000.048 - Human IFN-γ ELISA Kit
- 851.560.001 - Human IFN-γ ELISA Set
- 861.050.001 - Murine IFN-γ ELISA Set
- 872.000.001 - Rat IFN-γ ELISA Set
- 856.051.001 - Human IFN-γ ELISpot Set
- 856.051.001PC - Human IFN-γ ELISpot Kit
- 862.031.001PC - Murine IFN-γ ELISpot Kit
- 867.011.001 - Rat IFN-γ ELISpot Set
- 867.011.001PC - Rat IFN-γ ELISpot Kit
- 869.060.010 - Human IFN-γ ELISpot Pair
- 870.050.010 - Murine IFN-γ ELISpot Pair
- 871.020.010 - Rat IFN-γ ELISpot Pair
- 853.670.000 - Anti-Human IFN-γ Azide Free
- 856.051.001PCS - Human IFN-γ EasySplit ELISpot Kit
- 862.031.001PCS - Murine IFN-γ EasySplit ELISpot Kit
BACKGROUND
Different populations of T-cells secrete differing patterns of cytokines that ultimately lead to different immune responses. IFNg production is a key function of Th1, CD8+ CTLs and also NK cells. IFNg is a cytokine critical for cell mediated immunity against viral and intracellular bacterial infections and is involved in the inflammatory response following secretion via macrophage activation and stimulation of antibody secretion. IFNg is the hallmark effector cytokine of Th1 and therefore is an excellent marker for identifying a host response to intracellular pathogens.
IFNg is produced during infection by T cells of the cytotoxic/suppressor phenotype (CD8) and by a subtype of helper T cells, the Th1 cells. Th1 cells secrete IL-2, IL-3, TNFa and IFNg, whereas Th2 cells mainly produce IL-3, IL-4, IL-5, and IL-10, but little or no IFNg. IFNg preferentially inhibits the proliferation of Th2 but not Th1 cells, indicating that the presence of IFNg during an immune response will result in the preferential proliferation of Th1 cells.
In addition, IFNg has several properties related to immunoregulation. IFNg is a potent activator of mononuclear phagocytes, and activates macrophages to kill tumor cells by releasing reactive oxygen intermediates and TNFa. IFNg induces or augments the expression of MHC antigens on macrophages, T and B cells and some tumor cell lines. On T and B cells IFNg promotes differentiation. It enhances proliferation of activated B cells and can act synergistically with IL-2 to increase immunoglobulin light-chain synthesis.
The role of IFNg as a disease marker has been demonstrated for a number of different pathological situations including, viral infection, Autoimmune disease, transplant rejection, Diabetes and allergy.
Version 25 - 09.22
For research use only
For any order, the purchaser acknowledges having read and accepted the terms and conditions described on the Diaclone website.